Maven Clinic, the largest virtual clinic specialising in women’s and family health, has announced an expansion of its Fertility and Family Building program. The update introduces earlier diagnostic lab testing, condition-specific care pathways, and the first integration of FDA-listed ovulation prediction insights from ŌURA into a fertility care platform. These enhancements are designed to provide members with answers earlier in their journey and accelerate the transition to appropriate clinical care. The rollout is scheduled to begin this spring, with additional capabilities continuing to launch throughout 2026.

The expansion addresses significant economic and clinical challenges within the fertility sector, where 70% of employers have reported rising costs over the last three years. Despite 85% of infertility cases having identifiable underlying causes, individuals often spend an average of two years attempting to conceive before seeking professional support. This delay frequently results in unnecessary medical interventions and increased emotional stress.

Kate Ryder, founder and CEO of Maven Clinic, stated: "One of the most costly and least visible drivers of waste in our fertility system is delayed diagnosis, months or years spent trying without information, only to arrive at a clinic already behind. Time lost early becomes dollars spent later, in more aggressive treatment, higher-risk pregnancies, and preventable NICU stays. That's why Maven is building fertility care for the future, a connected system where data follows the member, lab diagnostics and wearable technology integrate, care teams cushion decision-making at every juncture and no family starts their journey already feeling like they're failing."

A key component of the updated Fertility and Family Building program is the integration of diagnostic testing directly into the care model. This includes hormone testing, genetic carrier screening, and foundational fertility panels that are typically ordered later in the process. By identifying issues such as hormonal imbalances or ovulatory disorders sooner, members can enter specialist care with established data, reducing delays and avoiding repeat testing. Results are managed within the Maven platform, allowing for direct consultation with providers to determine next steps. Additionally, the program introduces dedicated support for conditions like PCOS—which affects 10–13% of reproductive-age women, as well as endometriosis and oncofertility, the latter in partnership with Color Health.

• Early Diagnostic Access: Members can now access hormone testing, genetic carrier screening, and foundational fertility panels earlier in their journey to identify underlying barriers to conception.
• Wearable Integration: The platform features the first integration of FDA-listed ovulation prediction insights from ŌURA, providing real-time, clinically validated cycle data to members and care teams.
• Condition-Specific Pathways: New dedicated support programs address common fertility challenges, including PCOS, endometriosis, and oncofertility (in collaboration with Colour Health).
• AI-Powered Personalization: Maven Intelligence utilises AI to personalise the care experience by surfacing insights and tailoring guidance based on lab results and wearable data.
• Clinical and Financial Impact: The program has resulted in 30% of members conceiving without assisted reproductive technology and offers an average saving of $9,600 per birth for employers.
• Phased Rollout: New capabilities will begin launching this spring, with continued updates and features expected through 2026.
• Platform Connectivity: Future updates aim to create a more continuous view of the fertility journey by connecting virtual platform data with physical clinic partners.
  

The program’s technological foundation is powered by Maven Intelligence, an AI-powered orchestration layer that synthesizes data from lab results, clinical inputs, and wearable devices. As part of this strategy, Maven is the first partner to integrate continuous, clinically validated cycle insights from ŌURA to help members and care teams understand optimal timing for conception or when to adjust treatment pathways. These data-driven improvements have already contributed to measurable outcomes: 30% of members achieve pregnancy without assisted reproductive technology, and employers save an average of $9,600 per birth across fertility and maternity care. Furthermore, 88% of members report being more productive at work during their treatment. Future developments for the Fertility and Family Building experience include deeper connectivity with physical clinic partners and the creation of cohort-based insights to improve treatment adherence and support.